Group 1 - The core point of the article is that Jilin Aodong Pharmaceutical Group Co., Ltd. has received a drug registration certificate for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - As of the first half of 2025, the revenue composition of Jilin Aodong is as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - The current market capitalization of Jilin Aodong is 22.5 billion yuan [1]

吉林敖东公告，控股子公司洮南药业近日收到国家药品监督管理局颁发的"升陷汤颗粒"药品注册证书。 升陷汤颗粒是以黄芪、柴胡、升麻、知母、桔梗为主要成分的中药颗粒剂，适用于益气升陷。该药品为 处方药，注册分类为中药3.1类，药品批准文号为国药准字C2025万，有效期至2030年9月15日。此次证 书的获得有助于丰富公司产品种类，增强核心竞争力，但预计短期内不会对公司业绩产生重大影响。 ...

Group 1 - The core point of the announcement is the convening of the 2025 First Extraordinary General Meeting of Shareholders by Jilin Aodong Pharmaceutical Group Co., Ltd. to protect investors' rights and facilitate voting [2][3] - The meeting will adopt a combination of on-site and online voting methods, ensuring compliance with relevant laws and regulations [3][5] - The meeting is scheduled for September 19, 2025, at 14:00, with online voting available from 9:15 to 15:00 on the same day [4][5] Group 2 - The equity registration date for the meeting is set for September 12, 2025, allowing eligible shareholders to attend [6] - Attendees include ordinary shareholders, company directors, supervisors, senior management, and other relevant personnel [7] - The meeting will take place at the company's office in Dunhua City, Jilin Province [7] Group 3 - The agenda includes proposals that have been approved by the company's board and supervisory committee, with details available in previously disclosed materials [8] - Certain proposals require a special resolution, needing more than two-thirds of the voting rights, while others require a simple majority [8] - Separate counting of votes from minority investors will be conducted, excluding certain major shareholders and company executives [8] Group 4 - Shareholders wishing to attend must register in advance, with specific documentation required for both corporate and individual shareholders [9][10] - Registration will be open from September 15, 2025, during specified hours [10] - Contact information for the company is provided for further inquiries regarding the meeting [12]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-051 吉林敖东药业集团股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1.吉林敖东药业集团股份有限公司已于2025年8月30日发布《关于召开2025 年第一次临时股东大会的通知》（公告编号：2025-047），为进一步保护投资者 的合法权益，方便股东行使股东大会表决权，现发布《关于召开2025年第一次临 时股东大会的提示性公告》。 2.本次股东大会采取现场投票与网络投票相结合的方式。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第十 八次会议决议召开公司2025年第一次临时股东大会（以下简称"本次股东大 会"），本次股东大会采用现场投票和网络投票相结合的表决方式，现将有关事 项通知如下： 一、召开会议基本情况 1.股东大会届次：2025年第一次临时股东大会 2.股东大会的召集人：公司董事会 4.会议召开的日期、时间 （1）现场会议召开的日期、时间：2025年9月19日（星期五）下午14:00开 始。 ...

Core Viewpoint - Jilin Aodong's stock performance shows a mixed trend with a year-to-date increase of 13.98% and a recent decline over the past 20 days, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of September 11, Jilin Aodong's stock price increased by 2.00% to 19.35 CNY per share, with a trading volume of 1.94 billion CNY and a turnover rate of 0.85%, resulting in a total market capitalization of 231.41 billion CNY [1]. - The stock has seen a year-to-date increase of 13.98%, a 2.60% rise over the last five trading days, a 1.38% decline over the last 20 days, and a 21.35% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Jilin Aodong reported a revenue of 1.126 billion CNY, a year-on-year decrease of 20.21%, while the net profit attributable to shareholders was 1.282 billion CNY, reflecting a significant year-on-year increase of 138.44% [2]. Group 3: Shareholder and Dividend Information - Since its A-share listing, Jilin Aodong has distributed a total of 4.43 billion CNY in dividends, with 1.647 billion CNY distributed over the past three years [3]. - As of June 30, 2025, the number of shareholders decreased to 66,000, while the average circulating shares per person increased by 1.62% to 18,059 shares [2][3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 15.0138 million shares, an increase of 4.6149 million shares from the previous period [3].

Core Viewpoint - Jilin Aodong's Anshen Bnona Liquid has maintained a leading position in the domestic market for over 42 years, achieving cumulative sales of 8 billion bottles and a market share exceeding 80% [1][12] Group 1: Product Quality and Market Position - Anshen Bnona Liquid is recognized as a core product of Jilin Aodong, generating a total profit of 2.1 billion yuan and contributing 1.5 billion yuan in taxes to the state [1] - The product has been included in the first batch of protected traditional Chinese medicine varieties and the national medical insurance catalog, highlighting its significance in the industry [1][8] - The product's success is attributed to the use of high-quality, authentic medicinal materials sourced from the Changbai Mountain region, particularly the purebred velvet antler from the local deer [2][3] Group 2: Technological Innovation and Quality Control - Jilin Aodong has implemented modern production techniques, resulting in a 15% higher content of active ingredients like uridine and IGF-1 compared to ordinary deer antler [3][6] - The company has developed advanced technologies such as computer-controlled extraction and near-infrared online detection, ensuring product safety and consistency [6][8] - Continuous research and development efforts have led to the enhancement of production processes and quality standards, including the addition of new testing methods for raw materials [7][10] Group 3: Strategic Development and Policy Support - The company is positioned as a leading enterprise in the agricultural industrialization of Jilin Province, benefiting from government support for the development of the velvet antler industry [11] - Recent provincial policies encourage the secondary development of classic formulas and emphasize quality certification, aligning with Jilin Aodong's strategic goals [11] - The company aims to transform Anshen Bnona Liquid into a "ten billion-level product" by leveraging its market foundation and scientific breakthroughs [10][11]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-050 吉林敖东药业集团股份有限公司 股东股份质押与解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 注：（1）上述表中"比例"为四舍五入保留两位小数后的结果，下同。 （2）本公告中公司总股本数据为截至 2025 年 8 月 31 日的股份总数 1,195,895,387 股，下同。 1 吉林敖东药业集团股份有限公司（以下简称"公司"）接到股东敦化市金诚 实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有公司的 部分股份办理质押及解除质押手续，具体事项如下： （一）股东股份质押 1、股东股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 数量(万 | 占其所持 | 占公司总 | 是否 为限 | 是否为 补充质 | 质押起始日 | 质押到期日 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一 ...

Core Viewpoint - The announcement from Jilin Aodong Pharmaceutical Group indicates that shareholder Dunhua Jincheng Industrial Co., Ltd. has engaged in share pledges and releases, reflecting ongoing financial activities and management of equity stakes [1] Group 1: Share Pledge Details - On September 8, Jincheng Company pledged 15.55 million shares, accounting for 4.75% of its holdings and 1.30% of the company's total share capital, with the pledgee being China Merchants Securities [1] - On September 9, Jincheng Company released 14 million shares from pledge, representing 4.28% of its holdings and 1.17% of the company's total share capital, with the pledgee being Zheshang Securities [1] - As of the announcement date, Jincheng Company has cumulatively pledged shares amounting to 32.84% of its holdings, which is 8.98% of the company's total share capital [1] Group 2: Risk Assessment - The company states that Jincheng Company has good creditworthiness, and the risks associated with the pledges are controllable, indicating no change in control or risk of forced liquidation [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yanji Pharmaceutical, received a drug registration certificate for Terbutaline Sulfate Nebuliser Solution, enhancing the company's product portfolio and core competitiveness [1][3]. Drug Registration Details - The drug is classified as a chemical drug of category 4, with a specification of 2ml:5mg and a shelf life of 24 months [1][2]. - The drug is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [3]. Impact on the Company - The acquisition of the drug registration certificate is expected to improve the company's product structure and diversify its product offerings, creating favorable conditions for steady development [3]. - The company plans to comply with relevant laws and regulations while conducting production and sales of the new product, although the sales performance may be influenced by market conditions [3].

Group 1 - The core point of the article is that Jilin Aodong has received a drug registration certificate for "Sulfuric Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of September 5, indicating a significant regulatory approval for the company's product [2] - The product is expected to enhance the company's portfolio in the pharmaceutical sector, particularly in respiratory treatments [2] - This approval may lead to increased market opportunities and potential revenue growth for Jilin Aodong [2]